Frank Rouby

765 total citations
21 papers, 528 citations indexed

About

Frank Rouby is a scholar working on Toxicology, Pharmacology and Epidemiology. According to data from OpenAlex, Frank Rouby has authored 21 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Toxicology, 5 papers in Pharmacology and 5 papers in Epidemiology. Recurrent topics in Frank Rouby's work include Opioid Use Disorder Treatment (4 papers), Pharmacovigilance and Adverse Drug Reactions (4 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (2 papers). Frank Rouby is often cited by papers focused on Opioid Use Disorder Treatment (4 papers), Pharmacovigilance and Adverse Drug Reactions (4 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (2 papers). Frank Rouby collaborates with scholars based in France, Switzerland and New Zealand. Frank Rouby's co-authors include Joëlle Micallef, Vincent Pradel, Maryse Lapeyre‐Mestre, Vanessa Pauly, Élisabeth Frauger, Xavier Thirion, M.-J. Jean-Pastor, M Biour, Marc Bardou and Julien Kirchgesner and has published in prestigious journals such as Neuropsychologia, Frontiers in Pharmacology and British Journal of Clinical Pharmacology.

In The Last Decade

Frank Rouby

20 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Rouby France 11 107 100 89 80 66 21 528
Michael A. Ueberall Germany 12 98 0.9× 64 0.6× 134 1.5× 84 1.1× 12 0.2× 28 588
Yongbin Li China 18 46 0.4× 117 1.2× 53 0.6× 293 3.7× 85 1.3× 55 1.1k
Tzu‐Ting Chen Taiwan 16 29 0.3× 76 0.8× 44 0.5× 42 0.5× 63 1.0× 44 602
Mahmoud Slim Canada 15 51 0.5× 102 1.0× 203 2.3× 62 0.8× 20 0.3× 40 785
G. Veyrac France 11 33 0.3× 56 0.6× 198 2.2× 53 0.7× 77 1.2× 41 531
Dominique Lossignol Belgium 16 122 1.1× 37 0.4× 578 6.5× 133 1.7× 23 0.3× 41 1.3k
Simon Tarp Denmark 19 62 0.6× 55 0.6× 106 1.2× 106 1.3× 53 0.8× 54 901
Henning Cuhls Germany 14 91 0.9× 82 0.8× 153 1.7× 64 0.8× 16 0.2× 35 815
Charles Piwko Canada 14 388 3.6× 81 0.8× 138 1.6× 39 0.5× 5 0.1× 33 912
S. Welch Canada 8 144 1.3× 176 1.8× 72 0.8× 30 0.4× 30 0.5× 10 724

Countries citing papers authored by Frank Rouby

Since Specialization
Citations

This map shows the geographic impact of Frank Rouby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Rouby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Rouby more than expected).

Fields of papers citing papers by Frank Rouby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Rouby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Rouby. The network helps show where Frank Rouby may publish in the future.

Co-authorship network of co-authors of Frank Rouby

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Rouby. A scholar is included among the top collaborators of Frank Rouby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Rouby. Frank Rouby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lacroix, Clémence, et al.. (2023). Antibiotic-induced neurological adverse drug reactions. Therapies. 79(2). 181–188. 2 indexed citations
2.
Lacroix, Clémence, Frank Rouby, Catherine Cassé‐Perrot, et al.. (2022). What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?. Frontiers in Pharmacology. 13. 883987–883987. 10 indexed citations
3.
Bardou, Marc, M Biour, Julien Kirchgesner, et al.. (2019). Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. European Journal of Clinical Pharmacology. 76(3). 449–457. 77 indexed citations
4.
Benzaquen, Michael, et al.. (2018). Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatology International. 38(7). 1297–1299. 30 indexed citations
5.
Rouby, Frank, et al.. (2017). Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?. European Journal of Clinical Pharmacology. 73(8). 1009–1018. 9 indexed citations
6.
Bobot, Mickaël, et al.. (2016). Un cas de thrombopénie aiguë au rituximab dans la leucémie lymphoïde chronique. La Revue de Médecine Interne. 38(5). 344–346. 1 indexed citations
7.
Benzaquen, Michael, et al.. (2016). Pyoderma gangrenosum paradoxal induit par l’adalimumab chez un patient psoriasique : efficacité de l’ustékinumab. Annales de Dermatologie et de Vénéréologie. 143(12). S252–S252.
8.
Rouby, Frank, et al.. (2014). Lupus cutané subaigu induit par la capécitabine : un cas. Annales de Dermatologie et de Vénéréologie. 141(10). 593–597. 3 indexed citations
9.
10.
Rouby, Frank, et al.. (2012). Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. European Journal of Clinical Pharmacology. 68(7). 1103–1107. 56 indexed citations
11.
Frauger, Élisabeth, Vanessa Pauly, Frank Rouby, et al.. (2011). Les systèmes d’évaluation de l’abus et de la dépendance des médicaments psychoactifs. Therapies. 66(3). 263–272. 9 indexed citations
12.
Chiche, Laurent, Frank Rouby, R Jean, et al.. (2011). Hypoglycémies sévères au tramadol : deux nouvelles observations d’un effet indésirable non référencé. La Revue de Médecine Interne. 32(11). 703–705. 10 indexed citations
13.
Rouby, Frank, Vincent Pradel, Élisabeth Frauger, et al.. (2011). Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’ as an indicator. Fundamental and Clinical Pharmacology. 26(2). 286–294. 38 indexed citations
14.
Khoury-Malhame, Myriam El, Emmanuelle Reynaud, Pilar Salgado‐Pineda, et al.. (2011). Amygdala activity correlates with attentional bias in PTSD. Neuropsychologia. 49(7). 1969–1973. 74 indexed citations
15.
Frauger, Élisabeth, Vincent Pradel, Charléric Bornet, et al.. (2011). Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundamental and Clinical Pharmacology. 25(6). 753–761. 18 indexed citations
16.
Frauger, Élisabeth, Vanessa Pauly, Vincent Pradel, et al.. (2010). Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundamental and Clinical Pharmacology. 25(5). 633–641. 41 indexed citations
17.
Pradel, Vincent, et al.. (2010). Assessment of Abuse Potential of Benzodiazepines from a Prescription Database Using ‘Doctor Shopping’ as an Indicator. CNS Drugs. 24(7). 611–620. 73 indexed citations
18.
Frauger, Élisabeth, Vanessa Pauly, Xavier Thirion, et al.. (2009). Estimation of clonazepam abuse liability: a new method using a reimbursed drug database. International Clinical Psychopharmacology. 24(6). 318–324. 20 indexed citations
19.
20.
Micallef, Joëlle, Marc Rey, Alexandre Eusébio, et al.. (2008). Antiparkinsonian drug‐induced sleepiness: a double‐blind placebo‐controlled study of L‐dopa, bromocriptine and pramipexole in healthy subjects. British Journal of Clinical Pharmacology. 67(3). 333–340. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Ueberall Breakdown of academic impact, for papers by Yongbin Li Breakdown of academic impact, for papers by Tzu‐Ting Chen Breakdown of academic impact, for papers by Mahmoud Slim Breakdown of academic impact, for papers by G. Veyrac Breakdown of academic impact, for papers by Dominique Lossignol Breakdown of academic impact, for papers by Simon Tarp Breakdown of academic impact, for papers by Henning Cuhls Breakdown of academic impact, for papers by Charles Piwko Breakdown of academic impact, for papers by S. Welch
Rankless by CCL
2026